Patents by Inventor Philip K. Liu

Philip K. Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10406250
    Abstract: We have developed a model system of HIV reservoirs in neural cells by generating chimeric phosphorothioate-modified oligodeoxynucleotides (sODN) that specifically interact with neural cell DNA or RNA, and that further comprise a sequence of the HIV genome. In particular, we have conjugated the chimera sODN to a delivery vehicle (e.g. a superparamagnetic iron oxide nanoparticle (SPIO)) and have demonstrated specific delivery to neural cells, in vitro and in vivo. These model systems can be used to screen for agents that specifically target latent viral infection. In particular, using the model system, we have developed suicide MRI contrast agents that can be used to reduce the number of neural cells which harbor the virus, also provided herein. Our model system is translatable to other latent viruses as well.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: September 10, 2019
    Assignee: The General Hospital Corporation
    Inventor: Philip K. Liu
  • Publication number: 20160263253
    Abstract: We have developed a model system of HIV reservoirs in neural cells by generating chimeric phosphorothioate-modified oligodeoxynucleotides (sODN) that specifically interact with neural cell DNA or RNA, and that further comprise a sequence of the HIV genome. In particular, we have conjugated the chimera sODN to a delivery vehicle (e.g. a superparamagnetic iron oxide nanoparticle (SPIO)) and have demonstrated specific delivery to neural cells, in vitro and in vivo. These model systems can be used to screen for agents that specifically target latent viral infection. In particular, using the model system, we have developed suicide MRI contrast agents that can be used to reduce the number of neural cells which harbor the virus, also provided herein. Our model system is translatable to other latent viruses as well.
    Type: Application
    Filed: November 14, 2014
    Publication date: September 15, 2016
    Inventor: Philip K. LIU
  • Patent number: 9195637
    Abstract: The font size of text included in web page content is proportionally scaled based on proportional container widths and/or a minimum readable font size. The proportional font scaling improves web content readability on small-screen devices while maintaining relative proportions of font sizes between text containers when the text containers are rendered at full display width.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: November 24, 2015
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Jorge Peraza, Philip K. Liu
  • Publication number: 20120110438
    Abstract: The font size of text included in web page content is proportionally scaled based on proportional container widths and/or a minimum readable font size. The proportional font scaling improves web content readability on small-screen devices while maintaining relative proportions of font sizes between text containers when the text containers are rendered at full display width.
    Type: Application
    Filed: November 3, 2010
    Publication date: May 3, 2012
    Applicant: Microsoft Corporation
    Inventors: Jorge Peraza, Philip K. Liu
  • Publication number: 20100310473
    Abstract: It is disclosed here that nucleic acid-based agents can be delivered to the brain of a human or non-human animal having a leakage in the blood brain barrier by administering the agents through the eye. Brain tissues and cells can be imaged in vivo (e.g., by magnetic resonance imaging) by linking a contrast agent to a targeting nucleic acid that can hybridize to a target nucleic acid located at the brain site to be imaged and administering the contrast agentltargeting nucleic acid conjugate through the eye. Similarly, a nucleic acid based drug (e.g., as an antisense nucleic acid or a therapeutic agent linked to a targeting nucleic acid that can hybridize to a target nucleic located at a disease site in the brain) can be administered through the eye to treat a brain disease.
    Type: Application
    Filed: July 30, 2008
    Publication date: December 9, 2010
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Philip K. Liu, Christina H. Liu